Key Highlights
- Net loss was USD 11.6 million versus USD 18.1 million a year earlier.
- The loss was USD 0.37 per share versus an estimated USD 0.21 loss.
- Research and development expense fell to USD 6.1 million from USD 10.5 million.
- Cash and cash equivalents were USD 5.6 million at September 30, 2026.
Smaller Loss on Lower Research Costs
Senti Biosciences Holdings, Inc. (NASDAQ:SNTI) reported a third-quarter net loss of USD 11,586 thousand versus USD 18,126 thousand, or USD 0.37 per share versus USD 0.69, compared with an estimated loss of USD 0.21 per share. Research and Development expense fell to USD 6,068 thousand from USD 10,516 thousand, and general and administrative expense was USD 6,273 thousand versus USD 6,432 thousand.
Total operating expenses were USD 12,341 thousand versus USD 16,948 thousand, and the loss from operations was USD 12,322 thousand versus USD 16,948 thousand after USD 19 thousand of collaboration Revenue from a related party.
Other Income and Nine-Month Results
Total other income was USD 736 thousand versus an expense of USD 1,178 thousand. GeneFab sublease income from a related party was USD 992 thousand versus an expense of USD 1,567 thousand, other income, net, was USD 427 thousand and a change in Fair Value of related-party convertible notes was a loss of USD 726 thousand.
For the nine months, net loss was USD 28,557 thousand versus USD 46,971 thousand, or USD 0.92 per share versus USD 2.25. Research and development was USD 19,116 thousand versus USD 29,826 thousand, and operating expenses included a USD 6,882 thousand gain on Lease modification.
Interest income was USD 43 thousand versus USD 166 thousand, and comprehensive loss equaled net loss at USD 11,586 thousand.
Nine-month general and administrative expense was USD 19,245 thousand versus USD 20,317 thousand, total operating expenses were USD 31,479 thousand versus USD 50,143 thousand and the loss from operations was USD 31,427 thousand versus USD 50,143 thousand. GeneFab sublease income was USD 2,068 thousand versus USD 1,732 thousand, and total other income was USD 2,870 thousand versus USD 3,172 thousand.
Platform and Funding
The company describes itself as a "clinical-stage biotechnology company developing next-generation cell and gene therapies" engineered with gene circuit platform technologies for patients with incurable diseases. Related-party research costs were USD 2,853 thousand versus USD 3,417 thousand in the quarter.
Cash and cash equivalents were USD 5.6 million at September 30, 2026, and net cash used in Operating Activities for the nine months was USD 28,457 thousand versus USD 36,569 thousand. The filing says financing improved Liquidity but that the company concluded substantial doubt continued to exist about its ability to continue as a going concern.
The filing also describes milestone payments tied to SENTI-202 that must be achieved on or before the seventh anniversary of the Merger closing, including USD 10.0 million upon filing and acceptance of a Biologics License Application.
Related-party research costs for the nine months were USD 6,651 thousand versus USD 11,073 thousand, and total liabilities measured at fair value were USD 6,297 thousand.
Items to Follow
Reference points include research spending against the cash balance, the GeneFab sublease line, related-party convertible notes and the Going Concern disclosure.






Please wait processing your request...